215 results about "Powder diffraction" patented technology

The invention discloses a preparation process of a Baloxavir marboxil and vitamin C eutectic crystal form. The X-ray powder diffraction pattern of the Baloxavir marboxil and vitamin C eutectic crystal form under Cu-Ka radiation has diffraction angle 2theta values of 8.7 + / -0.2 degrees, 10.4 + / -0.2 degrees, 10.7 + / -0.2 degrees, 13.1 + / -0.2 degrees, 13.8 + / -0.2 degrees, 14.2 + / -0.2 degrees, 15.7 + / -0.2 degrees, 16.1 + / -0.2 degrees, 16.3 + / -0.2 degrees, 17.4 + / -0.2 degrees, 18.5 + / -0.2 degrees, 19.8 + / -0.2 degrees, 19.8 + / -0.2 degrees, 20.1 + / -0.2 degrees, 20.8 + / -0.2 degrees, 20.9 + / -0.2 degrees, 21.6 + / and characteristic peaks exist at the positions of 25.6 + / -0.2 degrees, 26.4 + / -0.2 degrees, 26.7 + / -0.2 degrees, 27.1 + / -0.2 degrees, 28.0 + / -0.2 degrees, 28.2 + / -0.2 degrees, 29.7 + / -0.2 degrees, 29.9 + / -0.2 degrees and 31.3 + / -0.2 degrees. The eutectic crystal form of Baloxavir marboxil and vitamin C provided by the invention has stable physicochemical properties, excellent solid stability and mechanical stability, and can be stably stored for a long time, and the preparation method is simple and convenient, has good repeatability, and has important application value for the development of the medicine in the future.

The invention discloses a preparation process of a Baloxavir marboxil and L-tartaric acid eutectic crystal form. The X-ray powder diffraction pattern of the Baloxavir marboxil and L-tartaric acid eutectic crystal form under Cu-Ka radiation has diffraction angle 2theta values of 8.7 + / -0.2 degrees, 10.8 + / -0.2 degrees, 11.6 + / -0.2 degrees, 13.2 + / -0.2 degrees, 13.8 + / -0.2 degrees, 14.3 + / -0.2 degrees, 15.8 + / -0.2 degrees, 16.2 + / -0.2 degrees, 16.4 + / -0.2 degrees, 17.5 + / -0.2 degrees, 18.6 + / -0.2 degrees, 18.9 + / -0.2 degrees, 19.4 + / -0.2 degrees, 19.8 + / -0.2 degrees, 20.1 + / -0.2 degrees, 20.7 + / and characteristic peaks exist at the positions of 25.7 + / -0.2 degrees, 26.4 + / -0.2 degrees, 26.8 + / -0.2 degrees, 27.6 + / -0.2 degrees, 28.3 + / -0.2 degrees, 28.6 + / -0.2 degrees, 29.1 + / -0.2 degrees, 29.7 + / -0.2 degrees, 31.4 + / -0.2 degrees, 32.0 + / -0.2 degrees, 35.4 + / -0.2 degrees, 35.8 + / -0.2 degrees, 36.1 + / -0.2 degrees, 36.7 + / -0.2 degrees and 37.4 + / -0.2 degrees. The Baloxavir marboxil and L-tartaric acid eutectic crystal form provided by the invention has stable physicochemical properties, excellent solid stability and mechanical stability, and can be stably stored for a long time, the preparation method is simple and convenient, the repeatability is good, and the Baloxavir marboxil and L-tartaric acid eutectic crystal form has important application value for the development of the medicine in the future.

A crystalline aceclodine HCl hemihydrate of formula (I): having a DSC onset peak at a value between 137.08 DEG C and 139.08 DEG C and / or an X-ray powder diffraction pattern with a characteristic peak at 17.7 + / -0.2 and / or 20.47 + / -0.2, represented by a 2-theta value (2 theta).

The invention provides a novel sarpogrelate hydrochloride crystal form and a preparation method and application thereof, an X-ray powder diffraction pattern of a crystal with the novel crystal form has characteristic peaks at 2theta values of 10.88 + / -0.1 degrees, 16.64 + / -0.1 degrees and 18.83 + / -0.1 degrees, and a differential scanning calorimetry analysis pattern of the crystal has an endothermic peak at 153-156 DEG C. The crystal has excellent stability, solubility and hygroscopicity as well as relatively high bioavailability and purity, and meanwhile, the preparation method is simple, the crystallization condition is mild, the cost is low, and the crystal is suitable for industrial production and can be used for preparing related pharmaceutical preparations.

The invention relates to a crystal form of 2-acrylamide-2-methylpropanesulfonic acid potassium salt (ATBS.K). The X-ray powder diffraction pattern of the crystal form has characteristic peaks at 2 theta (+ / -0.1 degrees) of 13.1 degrees, 14.4 degrees, 16.3 degrees, 19.8 degrees, 23.5 degrees, 24.3 degrees, 26.9 degrees, 27.6 degrees, 29.3 degrees, 30.6 degrees, 31.6 degrees, 34.3 degrees, 36.1 degrees, 41.7 degrees, 44.6 degrees and 46.7 degrees.

The invention discloses an androdenafil citrate crystal form and a preparation method thereof, and particularly provides a crystal form A to a crystal form H of androdenafil citrate, and X-ray powder diffraction analysis spectrums respectively correspond to a figure 1 to a figure 8. Compared with amorphous androdenafil citrate, the androdenafil citrate with the crystal structure obtained by the invention has higher purity, better stability and dissolution performance while ensuring the effect of inhibiting the activity of PDE5 enzyme, so that higher bioavailability can be obtained, the safety of clinical application is improved, and the androdenafil citrate is more suitable for medicine application.

The invention provides a crystal form VII of free alkali of rafenasin and a preparation method of the crystal form VII. The refenasin free alkali crystal form VII is good in stability, simple in preparation process and suitable for industrial production, and an X-ray powder diffraction pattern of the refenasin free alkali crystal form VII is represented by 2theta + / -0.20 degrees and has characteristic peaks of 4.898 degrees, 10.742 degrees, 13.448 degrees, 14.065 degrees, 17.138 degrees, 17.376 degrees, 18.982 degrees, 19.860 degrees, 20.282 degrees and 21.766 degrees.

This invention provides a method for preparing and testing powder diffraction standards for determining internal residual stress, belonging to the field of residual stress detection. The powder standards prepared by this invention possess shape retention capabilities, meeting the requirements of the transmission diffraction optical path in non-destructive diffraction determination of internal residual stress. The powder, after being bonded with an adhesive, forms a blocky solid form, and standards of different sizes can be prepared according to the penetration depth of different diffraction sources on different substrate materials. Furthermore, the ratio of powder to adhesive can be adjusted to obtain different diffraction volume ratios. By testing the uniformity of diffraction peak intensity distribution in translational and rotational degrees of freedom, the uniformity of the internal lattice distribution and orientation of the standard sample can be determined, thereby testing and judging the uniformity of the standard sample.

A process for preparing (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide HCl-salt Crystalline Form A, wherein the HCl-salt Crystalline Form A is characterized by an X-ray powder diffraction (XRPD) pattern obtained by irradiation with copper K-alpha (Cu Kα) radiation comprising peaks at 14.7±0.2 and 17.5±0.2 degrees two-theta, which comprises the step of crystallizing the crystalline form from a solvent.

The present invention relates to the crystalline form of bipyrimidine compounds, as well as methods for preparing the same and their use. In particular, the present invention relates to crystalline form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazole-2-yl)bicyclo[2.2.2]octan-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, wherein the X-ray powder diffraction pattern of crystalline form I includes characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2° and 22.200±0.2°. Crystal form I possesses high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological activity, making it suitable for pharmaceutical preparations.

The invention discloses an OEA and PEA eutectic crystal and a preparation method and application thereof, the eutectic crystal comprises oleoyl ethanolamine and hexadecanamide ethanol according to a substance amount ratio of 1: 1-1: 1.2, and an X-ray powder diffraction pattern of the eutectic crystal has characteristic diffraction peaks when a 2 theta angle is 8.2 degrees + / -0.2 degrees, 12.5 degrees + / -0.2 degrees, 16.8 degrees + / -0.2 degrees, 21.3 degrees + / -0.2 degrees and 24.6 degrees + / -0.2 degrees. Compared with existing OEA, the eutectic crystal is higher in melting point and has more excellent stability. The preparation method of the OEA eutectic is simple, easy to control and good in reproducibility. According to the invention, the application convenience of the OEA is greatly improved, the cost in storage, transportation and use processes is saved, and the application range of the OEA is widened.

Provided are a computing device, a computing method, a program, and a machine learning model generation method for inferring a lattice volume from a distribution pattern of X-ray powder diffraction. A computing device (100) for inferring a lattice volume from a distribution pattern of X-ray powder diffraction includes an information acquisition unit (110) that acquires information related to the distribution pattern of X-ray powder diffraction, and an inference unit (120) that includes a machine learning model that takes information related to the distribution pattern of X-ray powder diffraction as input and outputs an inferred lattice volume, and infers the lattice volume from the information related to the distribution pattern of X-ray powder diffraction acquired by the information acquisition unit (110).

The invention discloses a crystal form of carboxamide triazole. The crystal form I shows characteristic peaks at the positions of 20.3 degrees + / -0.2 degrees, 22.1 degrees + / -0.2 degrees, 23.4 degrees + / -0.2 degrees, 25.2 degrees + / -0.2 degrees, 28.6 degrees + / -0.2 degrees and 28.9 degrees + / -0.2 degrees in an X-ray powder diffraction pattern expressed by a 2theta diffraction angle; the crystal form II shows characteristic peaks at the positions of 3.8 degrees + / -0.2 degrees, 14.9 degrees + / -0.2 degrees, 19.2 degrees + / -0.2 degrees, 22.3 degrees + / -0.2 degrees, 25.4 degrees + / -0.2 degrees and 28.9 degrees + / -0.2 degrees in an X-ray powder diffraction pattern represented by a 2theta diffraction angle; the crystal form III shows characteristic peaks at the positions of 3.4 degrees + / -0.2 degrees, 3.7 degrees + / -0.2 degrees, 12.1 degrees + / -0.2 degrees, 14.8 degrees + / -0.2 degrees, 20.2 degrees + / -0.2 degrees and 24.3 degrees + / -0.2 degrees in an X-ray powder diffraction pattern expressed by a 2theta diffraction angle.

The present application relates to allulose crystals, which have an X-ray powder diffraction pattern including peaks at 2θ diffraction angles of 18.8±0.5°, 15.2±0.5°, and 19.5±0.5° in X-ray powder diffraction (XRD) analysis, a sweetener composition containing allulose crystals, and a method for producing allulose crystals.

The application discloses an organic amine modified HMS molecular sieve and application thereof in carbon dioxide capture, and specifically relates to the following steps: first, preparing mesoporous molecular sieve HMS, which contains two kinds of pore structures, 4.5-8.0 nm and 11.5-17.5 nm respectively, and a single wide diffraction peak is presented at 2theta=2.6 degrees in X-ray powder diffraction; then, grafting amino silane on the surface of the mesoporous molecular sieve HMS; and finally, immersing the mesoporous molecular sieve HMS in an organic amine solution to obtain a multilevel organic amine modified HMS molecular sieve. The synthesis method is simple, the carbon dioxide adsorption efficiency is high, and the thermal stability is good.

The invention relates to a coated cutting tool. Specifically, the present invention relates to a coated cutting tool and a method of making such a coated cutting tool comprising a substrate coated with a multi-layer wear resistant coating comprising a layer of alpha-Al2O3 and a layer of titanium carbonitride, TixCyN1-y, deposited on the layer of alpha-Al2O3, where 0.85 < = x < = 1.3 and 0.4 < = y < = 0.85, wherein TixCyN1-y has a texture coefficient TC (hkl) measured by X-ray diffraction using CuK [alpha] radiation and [theta]-2 [theta] scan and defined according to the Harris formula, where I (hkl) is the measured intensity (integrated area) of (hkl) reflection; i0 (hkl) is the standard intensity according to the standard powder diffraction data of the JCPDS cards No. 42-1489; n is the number of reflections used in the calculation, and wherein the (hkl) reflections used are (1 1), (2 0), (2 0), (3 1), (3 1), (4 0) and (4 2); and TC (1 1) > = 3.

To provide methods for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.SOLUTION: A crystalline hydrate of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide is provided. Preferably, the hydrate is a hemihydrate. Preferably, the crystalline hydrate has an X-ray powder diffraction pattern characterized by peaks at 13.4±0.2, 15.1±0.2, and 21.7±0.2°2θ when measured at about 25°C with monochromatic Kα1 radiation.SELECTED DRAWING: None

The invention discloses a component quality testing method of a metal-plastic composite material for an electric bicycle. The component quality testing method comprises the following steps: (1) determining the types of metal elementary substances by using an X-ray powder diffraction method; (2) measuring the content of the metal elementary substance by using an X-ray fluorescence spectrometry; and (3) determining the plastic content by using a calcination method or an extraction method. According to the invention, whether the material to be detected is the metal-plastic composite material or not can be determined, the type and content of metal simple substances and the content of plastic in the composite material can be detected, the blank in the industry is filled, and the development and application of the composite material in the electric bicycle industry are promoted.

The invention discloses a polymorphic form of a fumarate of a 2-(3-(3-amino-4-(7H-pyrrolo [2, 3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl) isonicotinoyl) piperidine-4-yl) azetidin-3-yl) acetonitrile compound, and the crystal form A of the polymorphic form comprises the following characteristic peaks measured by reflection angles of 2 theta in an X-ray powder diffraction pattern: 8.69, 9.82, 11.58, 14.79, 15.54, 16.05, 17.82, 18.02, 18.55, 19.68 and 20.39. The invention further discloses a preparation method of the polymorphic form. The crystal form is good in stability and high in solubility. The invention further provides a preparation method of the fumarate crystal form and application of the fumarate crystal form in preparation of a JAK1 inhibitor.

The invention discloses a Bexagliflozin and vitamin C eutectic crystal form and a preparation method and application thereof. An X-ray powder diffraction pattern of a Bexagliflozin and vitamin C eutectic crystal under Cu-Ka radiation comprises peaks at the following 2 theta values: 10.5 + / -0.2 degrees, 10.8 + / -0.2 degrees, 11.1 + / -0.2 degrees, 11.9 + / -0.2 degrees, 12.8 + / -0.2 degrees, 15.5 + / -0.2 degrees, 16.0 + / -0.2 degrees, 16.2 + / -0.2 degrees, 17.4 + / -0.2 degrees, 18.7 + / -0.2 degrees, 19.1 + / -0.2 degrees, 19.8 + / -0.2 degrees, 20.7 + / -0.2 degrees, 21.2 + / -0.2 degrees, 22.4 + / -0.2 degrees, 22.8 + / -0.2 degrees, 23.3 + / - 21.8 + / -0.2 degrees, 22.4 + / -0.2 degrees, 22.7 + / -0.2 degrees, 23.5 + / -0.2 degrees, 24.4 + / -0.2 degrees, 24.7 + / -0.2 degrees, 24.9 + / -0.2 degrees, 25.3 + / -0.2 degrees, 25.8 + / -0.2 degrees, 26.7 + / -0.2 degrees, 27.2 + / -0.2 degrees, 27.5 + / -0.2 degrees, 28.0 + / -0.2 degrees, 29.5 + / -0.2 degrees, 30.0 + / -0.2 degrees, 30.1 + / -0.2 degrees, 30.9 + / -0.2 degrees, 31.4 + / -0.2 degrees and 31.7 + / -0.2 degrees.

The invention belongs to the technical field of lithium ion battery materials, and particularly relates to a crystal form of a lithium ion battery additive ethylene disulfate and a preparation method of the crystal form. An X-ray powder diffraction pattern of the crystal form A comprises 2theta values of 21.0 + / -0.2 degrees, 23.8 + / -0.2 degrees and 24.6 + / -0.2 degrees; an X-ray powder diffraction pattern of the crystal form B contains 2 theta values of 12.2 + / -0.2 degrees, 18.0 + / -0.2 degrees, 24.4 + / -0.2 degrees and 36.9 + / -0.2 degrees. The crystal form provided by the invention is large in particle size, easy to remove water, capable of obtaining a product with low water content, high in stability, controllable in crystal form, low in requirements on storage conditions and capable of being stably stored, and the transportation cost and the production cost are saved; and the battery capacity retention rate and the battery capacity recovery rate can be improved, the capacity fading of the battery is delayed, the internal resistance of the battery is reduced, and a better interface composition adjusting effect is achieved.

A processing device (400) for performing non-negative matrix factorization on measured X-ray powder diffraction profiles comprises a measurement profile acquisition section (410) for acquiring a plurality of measured profiles, a decomposition section (420) for applying non-negative matrix factorization to the measured profiles and for calculating base profiles; an index calculation section (430) for acquiring the base profiles and for calculating indices based on a non-uniformity of the base profiles; a base profile classification section (440) for classifying the base profiles into a plurality of groups based on the indices; and a base profile correction section (450) for performing a correction based on the indices on at least one of the plurality of groups and for calculating a corrected base profile.

The invention relates to a cefpirin crystal form of benzathine and a preparation method thereof. An X-ray powder diffraction (XRPD) spectrum of the cefpirin crystal form A represented by 2 theta contains characteristic peaks of 4.91 + / -0.2, 9.82 + / -0.2, 21.16 + / -0.2, 21.41 + / -0.2 and 24.68 + / -0.2. The cefpirin benzathine crystal form A is high in purity, low in impurity content, good in stability, uniform in particle size distribution and easy to prepare a suspension preparation. In addition, the preparation method is simple to operate, mild and easy-to-control in condition and suitable for industrial production.

The invention provides an L-seryl-L-histidine crystal form compound and a preparation method thereof, the L-seryl-L-histidine crystal form compound has a structure as shown in a formula I. The compound has characteristic peaks at least when a 2 theta value is 8.35 + / -0.2 degrees, 11.20 + / -0.2 degrees, 12.42 + / -0.2 degrees, 13.62 + / -0.2 degrees, 16.74 + / -0.2 degrees, 17.93 + / -0.2 degrees, 18.90 + / -0.2 degrees, 19.67 + / -0.2 degrees, 21.81 + / -0.2 degrees, 22.47 + / -0.2 degrees, 23.33 + / -0.2 degrees, 2451 + / -0.2 degrees, 25.61 + / -0.2 degrees and 27.59 + / -0.2 degrees in an X-ray powder diffraction pattern. Compared with amorphous powder obtained through liquid phase addition and freeze drying, the SH crystal is simpler in operation mode, lower in production cost, lower in energy consumption, higher in stability and convenient to produce and store.

To provide a stable crystalline form of a novel compound having excellent selective agonistic activity for melanocortin receptors, particularly melanocortin-4 receptor (MC4R), and a method for producing the same.SOLUTION: The present invention relates to crystalline form I of a compound represented by chemical formula 1, a pharmaceutically acceptable salt thereof, or a solvate thereof, the crystalline form I having three or more characteristic peaks selected from the following diffraction angles (2θ values) in an X-ray powder diffraction (XRPD) pattern: 8.240±0.2°, 9.363±0.2°, 10.2693±0.2°, 10.5969±0.2°, 12.050±0.2°, 12.841±0.2°, 13.503±0.2°, 15.5738±0.2°, 16.6030±0.2°, 17.009±0.2°, 17.305±0.2°, 18.364±0.2°, 18.7390±0.2°, 19.188±0.2°, 19.476±0.2°, 20.001±0.2°, 20.477±0.2°, 20.665±0.2°, 21.348±0.2°, 21.976±0.2°, 22.580±0.2°, 23.896±0.2°, 4.334±0.2°, 24.812±0.2°, 25.243±0.2°, 25.833±0.2°, 26.646±0.2°, 27.82±0.2°, 28.316±0.2°, 28.609±0.2°, 29.692±0.2°, 30.185±0.2°, and 30.875±0.2°.SELECTED DRAWING: None

The invention belongs to the technical field of crystal engineering, and discloses a lutein-glutamic acid eutectic crystal and a preparation method and application thereof, Cu-k alpha radiation is used, and the lutein-glutamic acid eutectic crystal has characteristic peaks at 21.75 + / -0.2 degrees, 25.95 + / -0.2 degrees, 31.34 + / -0.2 degrees and 35.96 + / -0.2 degrees in an X-ray powder diffraction pattern represented by a diffraction angle 2 theta. According to the lutein-glutamic acid eutectic crystal provided by the invention, on the premise of not changing the pharmacological activity of the lutein, the solubility and the dissolution rate of the lutein are remarkably improved, and the stability of the lutein-glutamic acid eutectic crystal under the conditions of high temperature, high humidity and strong light is greatly enhanced; in-vitro cell experiments further prove that compared with pure xanthophyll, the xanthophyll-glutamic acid eutectic has more excellent cell aging resistance, oxidation resistance and vasodilation promoting activity, and an ideal dosage form is provided for efficient application of xanthophyll in medicines and functional foods.

The invention belongs to the technical field of medicines, and particularly relates to a crystal form IV of an sGC agonist as well as a preparation method and application of the crystal form IV. The crystal form IV of the sGC agonist is the crystal form IV of a compound I. The crystal form IV has diffraction peaks at the positions of 9.2951 degrees, 17.9978 degrees, 18.5726 degrees, 19.7368 degrees, 21.6855 degrees and 25.2649 degrees in an X-ray powder diffraction spectrum represented by a diffraction angle of 2 theta + / -0.2 degrees. The crystal form IV of the sGC agonist LXH-1211 provided by the invention provides a technical guarantee for subsequent research and development of drugs and maintenance of consistency of pharmacokinetic and pharmacokinetic properties of the drugs, and also can provide a technical support for subsequent industrial production of drugs with specific crystal forms.

The invention provides a crystal form of an edoxaban intermediate and a preparation method thereof, and relates to the field of medicinal chemistry. The structural formula of the edoxaban intermediate is as shown in formula I; the crystal form of the edoxaban intermediate comprises a crystal form A, a crystal form B or a mixture of the crystal form A and the crystal form B in any proportion. The X-ray powder diffraction pattern of the crystal form A of the edoxaban intermediate has characteristic absorption peaks at the positions of 2theta angles of 11.20 degrees, 17.66 degrees, 18.61 degrees, 19.29 degrees and 27.40 degrees; the X-ray powder diffraction pattern of the crystal form B of the edoxaban intermediate has characteristic absorption peaks at the positions of 2 theta angles of 7.99 degrees, 10.82 degrees, 13.33 degrees, 18.22 degrees, 18.48 degrees, 19.34 degrees and 20.02 degrees. The stable crystal form of the compound shown in the formula I can be successfully obtained, the crystal form of the compound shown in the formula I can be directly used as an intermediate to be stored and used, and the synthesis route of edoxaban is simplified.

Provided are a crystal form of a five-membered and six-membered compound, a preparation method and application thereof, in particular, a crystal form A, a crystal form B, a crystal form C, a crystal form D, a crystal form F, a crystal form G, a crystal form H, a crystal form I or a crystal form J of a five-membered and six-membered compound as shown in formula X. The crystal form A has an X-ray powder diffraction pattern expressed by a 2θ angle using Cu-Kα radiation, and has diffraction peaks at 6.9±0.2°, 11.2±0.2°, 12.2±0.2°, 13.7±0.2°, 17.3±0.2°, 18.2±0.2° and 24.3±0.2°. The crystal form of the five-membered and six-membered compound provided has an inhibitory or / and degrading effect on IRAK4, has potential clinical application value, is expected to improve the prognosis of patients and reduce the possibility of drug resistance, and has good solubility, physical and chemical stability and mechanical stability.

The invention discloses a beta crystal form of arfamarin as well as a preparation method and application thereof, and relates to the technical field of anthelmintics for dogs, the crystal form is a hydrate crystal form, and the molecular formula is C26H19ClF9N3O4; the X-ray powder diffraction pattern of the crystal form is shown as follows: 2theta = 5.38 degrees, 8.10 degrees, 9.79 degrees, 12.43 degrees, 13.71 degrees, 13.91 degrees, 14.86 degrees, 15.15 degrees, 15.56 degrees, 16.26 degrees, 16.84 degrees, 17.38 degrees, 17.71 degrees, 18.33 degrees, 18.78 degrees, 19.64 degrees, 19.93 degrees, 20.68 degrees, 21.54 degrees, 22.16 degrees, 22.49 degrees, 23.68 degrees, 24.14 degrees, 24.67 degrees, 25.05 degrees, 25.50 degrees, 26.53 degrees, 27.27 degrees, 28.01 degrees, 29.21 degrees, 29.79 degrees, 30.16 degrees, 31.35 degrees, 31.89 degrees, 32.75 degrees, 33.33 degrees The infrared spectrum of the crystal form at least has characteristic peaks at 3360 cm <-1 >, 3070 cm <-1 >, 1705 cm <-1 >, 1641 cm <-1 >, 1534 cm <-1 >, 1327 cm <-1 >, 1170 cm <-1 > and 829 cm <-1 >. A differential scanning calorimetry (DSC) curve of the crystal form shows that a desolventizing endothermic peak exists in an interval of 61.0 DEG C to 102.4 DEG C.